Example: bachelor of science
WHEN AND HOW TO PRESCRIBE STATINS
The appropriate intensity of statin therapy should be initiated or continued: 1. Clinical ASCVD a. Age ≤75 y and no safety concerns: High-intensity statin I A b. Age >75 y or safety concerns: Moderate-intensity statin I A 2. Primary prevention—Primary LDL-C ≥190 mg/dL a.
Tags:
Information
Domain:
Source:
Link to this page:
Related documents
Summary of National Guidance for Lipid Management for ...
www.england.nhs.uklow- or medium-intensity statin the likely benefits and potential risk of side effects if changed to a high-intensity statin when they have a medication review and agree with the person whether a change is needed. Ezetimibe, alirocumab, evolocumab or inclisiran can be added when patients’
CORCAL RESEARCH STUDY - Intermountain Healthcare
intermountainhealthcare.orgmoderate-intensity statin therapy. · A greater than 20 percent risk is considered high. It is recommended that you start with high-intensity statin therapy. What should I do now? Talk with your primary care provider to discuss the treatment option that is …
2022 HEDIS® Measures
www.mclaren.orgStatin Therapy for Patients with Cardiovascular Disease • Men dispensed a high or moderate21-75 • Women 40-75 Percent of members who were identified as having clinical atherosclerotic cardiovascular disease (ASCVD) who were -intensity statin medication. Two rates are reported: • Received statin therapy; dispensed at least one
Table 5. Statin Dose Intensity and Equivalency Chart* - MQIC
www.mqic.orgStatin Intensity %LDL-C Reduction HMG-CoA Reductase Inhibitor Rosuvastatin Atorvastatin Pitavastatin Simvastatin Lovastatin Pravastatin Fluvastatin High-Intensity (lowers LDL-C ≥ 50%) 63 40 mg ($196) 62 61 60 80mg ($9 gen, $ 236. br) 59 58 56 20 mg 54 ($196) 52 10 mg ($196) 50 40mg ($9 gen, $ 236. br) Moderate-
Simplified lipid guidelines - Canadian Family Physician
www.cfp.castatins, statin therapy should be maximized first(to high intensity) (high-level evidence). Follow-up • The use of cholesterol targets for reducing CVD is not required (high-level evidence). • We suggest that the monitoring of repeat lipid levels after a patient begins lipid-lowering therapy is not required (low-level evidence).
Guidance for the management of hypertriglyceridaemia
www.ncl-mon.nhs.ukStatin Guidance, Appendix 1). Review in 2-3 months Low CVD risk High risk or established CVD of pancreatitis lifestyle, review in 3-6 months Offer ... Physical activity (at least 150 minutes of moderate intensity aerobic activity or 75 minutes of vigorous intensity aerobic activity)